Category Archives: nyse

The Dead Model

Click to enlarge How Lucky Do You Feel? Nine years ago, I wrote about the so-called “Fed Model.” The insights there are still true, though the model has yielded no useful signals over that time. It would have told you to remain in stocks, which given the way many panic, would not have been a bad decision. I’m here to write about a related issue this evening. To a first approximation, most investment judgments are a comparison between two figures, whether most people want to admit it or not. Take the “Fed Model” as an example . You decide to invest in stocks or not based on the difference between Treasury yields and the earnings yield of stocks as a whole. Now with interest rates so low, belief in the Fed Model is tantamount to saying “there is no alternative to stocks.” [TINA] That should make everyone take a step back and say, “Wait. You mean that stocks can’t do badly when Treasury yields are low, even if it is due to deflationary conditions?” Well, if there were only two assets to choose from, a S&P 500 index fund and 10-year Treasuries, and that might be the case, especially if the government were borrowing on behalf of the corporations. Here’s why: in my prior piece on the Fed Model, I showed how the Fed Model was basically an implication of the Dividend Discount Model. With a few simplifying assumptions, the model collapses to the differences between the earnings yield of the corporation/index and its cost of capital. Now that’s a basic idea that makes sense, particularly when consider how corporations work. If a corporation can issue cheap debt capital to retire stock with a higher yield on earnings, in the short-run it is a plus for the stock. After all, if the markets have priced the debt so richly, the trade of expensive debt for cheap equity makes sense in foresight, even if a bad scenario comes along afterwards. If true for corporations, it should be true for the market as a whole. The means the “Fed Model” is a good concept, but not as commonly practiced, using Treasuries – rather, the firm’s cost of capital is the tradeoff. My proxy for the cost of capital for the market as a whole is the long-term Moody’s Baa bond index, for which we have about 100 years of yield data. It’s not perfect, but here are some reasons why it is a reasonable proxy: Like equity, which is a long duration asset, these bonds in the index are noncallable with 25-30 years of maturity. The Baa bonds are on the cusp of investment grade. The equity of the S&P 500 is not investment grade in the same sense as a bond, but its cash flows are very reliable on average. You could tranche off a pseudo-debt interest in a way akin to the old Americus Trusts , and the cash flows would price out much like corporate debt or a preferred stock interest. The debt ratings of most of the S&P 500 would be strong investment grade. Mixing in equity and extending to a bond of 25-30 years throws on enough yield that it is going to be comparable to the cost of capital, with perhaps a spread to compensate for the difference. As such, I think a better comparison is the earnings yield on the S&P 500 vs the yield on the Moody’s BAA index if you’re going to do something like the Fed Model. That’s a better pair to compare against one another. Click to enlarge A new take on the Equity Premium! That brings up another bad binary comparison that is common – the equity premium. What do stock returns have to with the returns on T-bills? Directly, they have nothing to do with one another. Indirectly, as in the above slide from a recent presentation that I gave, the spread between the two of them can be broken into the sum of three spreads that are more commonly analyzed – those of maturity risk, credit risk and business risk. (And the last of those should be split into an economic earnings factor and a valuation change factor.) This is why I’m not a fan of the concept of the equity premium . The concept relies on the idea that equities and T-bills are a binary choice within the beta calculation, as if only the risky returns trade against one another. The returns of equities can be explained in a simpler non-binary way, one that a businessman or bond manager could appreciate. At certain points lending long is attractive, or taking credit risk, or raising capital to start a business. Together these form an explanation for equity returns more robust than the non-informative academic view of the equity premium, which mysteriously appears out of nowhere. Summary When looking at investment analyses, ask “What’s the comparison here?” By doing that, you will make more intelligent investment decisions. Even a simple purchase or sale of stock makes a statement about the relative desirability of cash versus the stock. ( That’s why I prefer swap transactions .) People aren’t always good at knowing what they are comparing, so pay attention, and you may find that the comparison doesn’t make much sense, leading you to ask different questions as a result. Disclosure: None

Biomeds And Banks In Basing Mode After A Strong Week

Generic drug and biotech firms scored two of the top three gains among industries this past week. Super regional banks, led by BB&T ( BBT ), SunTrust Banks ( STI ), Northern Trust ( NTRS ) and Fifth Third Bancorp ( FITB ), was the other fast-rising group. The biotech group rose 6% for the week. The gain was disproportionately influenced by some thinly-traded names, particularly Amphastar ( AMPH ),  a maker of injectable and inhalable drugs. It surged 16% on the week. Emergent BioSolutions ( EBS ) popped 6% for the week, putting it at a new high and in buy range above a 41.06 buy point in a double-bottom-with-handle base.  Emergent’s bread-and-butter product BioThrax is an anthrax vaccine. Emergent is also planning to spin off its Aptevo Therapeutics subsidiary, which has a prostate cancer treatment in clinical trials, later this year. Analysts project a 3% earnings decline this year, followed by a 73% rebound in 2017. Another potential group leader is IBD 50 stock Medivation ( MDVN ).  Owner of the prostate cancer treatment Xtandi, Medivation shares are up 24% since clearing a 48.87 buy point in April. Investors who opted out of that back-and-forth breakout could look at the chart as a 14-month cup pattern, which puts shares just below a 63.04 handle buy point. Medivation is under uncertain pressure from France’s pharma giant Sanofi ( SNY ), which is reportedly gearing up for a board battle after Medivation declined the company’s $9.3 billion takeover offer last month. Analysts consensus plots a 31% EPS gain this year, rising 63% in 2017.  Sales are expected to slip 1% in 2016, rebounding to a 26% gain next year. One other biotech worth mentioning is Incyte ( INCY ). The Delaware-based specialist in blood cancer treatments is up since April 1, but needs more work on building the right side of a potential new base.  Its Relative Strength Rating is sickly and the stock remains deep below its 40-week moving average. But analysts project a 222% revenue gain this year, partly due to its acquisition of the European operations of Ariad Pharmaceuticals, set to close in June, followed by sharp rebound to profitability next year. Among generic drug makers, Allergan ( AGN ) and Akorn ( AKRX ) show some of the more telling chart action in the group. Allergan rose almost 3%, to just below its 10-week moving average, a line that has acted as a ceiling for the stock since early January. Akorn retook its 10-week line the previous week, then quickly advanced to push through resistance at its 40-week line. Allergan has no possible buy point in sight, and Akorn needs time if its current consolidation is to become a base. The RS ratings for both stocks are dismal, but their fundamentals remain sound, and an upturn in institutional investor for the stocks would count as a positive for the market. Beyond the drug trade, banks also posted a strong week, buoyed by rising indications that the Federal Reserve is leaning toward a rate hike in June.  Investment banks also took strength from JPMorgan Chase ’s ( JPM ) announcement on Tuesday that it would lift its dividend by 9%. SunTrust, Northern Trust and Fifth Third have all technically formed cup-with-handle patterns. SunTrust and Northern Trust show the strongest Relative Strength Ratings, and the handles of their base patterns have formed above 10-week support. One other factor to note: All four banks show Accumulation/Distribution Ratings of B- or better, suggesting they are seeing strong buying interest from institutional investors.

Amazon Looks Primed To Disrupt Wal-Mart, Target, CVS, Walgreens

A major expansion by Amazon.com ( AMZN ) into private-label goods, which could come this month, elevates its ability to further challenge legacy retailers across the board. Cowen analyst John Blackledge estimates Amazon will be the No. 2 player in the $425 billion consumable market, excluding food and beverage, surpassing  Walgreens Boots Alliance ( WBA ), CVS Health ( CVS ) and Target ( TGT ) but still lagging well behind market leader Wal-Mart ( WMT ). He defines consumables as four segments: personal care products, household products, baby products and pet products. Blackledge also estimates Amazon will be a top-10 player in the $785 billion food and beverage grocery market by 2019. “We are encouraged by Amazon’s growing footprint in this category, which we see as ripe for potential disruption, given younger demos increasingly purchasing grocery items via digital channels,” Blackledge wrote. The leader in the food and beverage category is Wal-Mart, followed by Kroger ( KR ), Albertsons/Safeway and Costco Wholesale ( COST ). Last week, the Wall Street Journal  cited people familiar with the matter as saying Amazon is set in the coming weeks to roll out new lines of private-label brands that will include its first broad push into perishable foods. According to the Private Label Manufacturers Association, sales of private-label store brands in the U.S. topped $118 billion in 2015, with supermarkets and drug chains accounting for over $70 billion of the total. In the grocery and consumables market, Blackledge says, Amazon’s growth has come at the expense of Wal-Mart, Target. Walgreens and CVS. Amazon’s key competitive advantage is its multiplatform approach with Amazon Prime, which includes same-day delivery for many goods, “all of which should lead to rising number of consumers skipping the trip to the local supercenter, drug store or grocery market,” he wrote. Amazon has sold private-label products since 2009, primarily under the AmazonBasics brand, though that effort has concentrated largely on consumer electronics. Amazon stock rose 0.6% to 702.80 in the stock market today . Amazon stock hit an all-time high of 722.45 on May 12. It carries a strong IBD Composite Rating of 94, putting it among the top 6% of all stocks on key metrics such as revenue growth. Walgreens climbed 1.3% but CVS fell 1.5%. Target climbed 2.4%. Wal-Mart advanced 1%, hitting a nine-month high intraday, after spiking nearly 10% Thursday on strong earnings and same-store sales.